ARTFORCE is a consortium of top clinical centers and SME’s in Europe aiming at improving outcome and reducing clinical and economical burden of treatments in non-small cell lung and advances head and neck cancer.
Head and neck cancer:
Concomitant chemoradiation is the standard of care for head and neck cancer. It is the aim of the consortium to improve the outcome
- for patients suffering from stage III/IV head and neck cancer by:
- predictive rather than prognostic pretreatment measurements
- adaptive radiation with beyond state of the art quality control
- for patients with non-small cell lung cancer by:
- dose escalation based upon pretreatment FDG-PET images
- validating and testing predictive biomarkers
- adaptive radiation with beyond state of the art quality control
It is our aim to investigate the impact of these strategies on patients treated within the consortium.